Impact of Bevacizumab on Visual Function, Tumor Size, and Toxicity in Pediatric Progressive Optic Pathway Glioma: A Retrospective Nationwide Multicentre Study
Backgrounds: Bevacizumab (BVZ) is used as a subsequent line of treatment for pediatric optic pathway glioma (OPG) in the case of progression. Data on the treatment effect concerning tumor progression and visual function are scarce and nationwide studies are lacking. Methods: We performed a retrospec...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/24/6087 |
| _version_ | 1797461099188060160 |
|---|---|
| author | Carlien A. M. Bennebroek Judith van Zwol Giorgio L. Porro Rianne Oostenbrink Anne T. M. Dittrich Annabel L. W. Groot Jan W. Pott Etienne J. M. Janssen Noël J. Bauer Maria M. van Genderen Peerooz Saeed Maarten H. Lequin Pim de Graaf Antoinette Y. N. Schouten-van Meeteren |
| author_facet | Carlien A. M. Bennebroek Judith van Zwol Giorgio L. Porro Rianne Oostenbrink Anne T. M. Dittrich Annabel L. W. Groot Jan W. Pott Etienne J. M. Janssen Noël J. Bauer Maria M. van Genderen Peerooz Saeed Maarten H. Lequin Pim de Graaf Antoinette Y. N. Schouten-van Meeteren |
| author_sort | Carlien A. M. Bennebroek |
| collection | DOAJ |
| description | Backgrounds: Bevacizumab (BVZ) is used as a subsequent line of treatment for pediatric optic pathway glioma (OPG) in the case of progression. Data on the treatment effect concerning tumor progression and visual function are scarce and nationwide studies are lacking. Methods: We performed a retrospective, nationwide, multicentre cohort study including all pediatric patients with OPG treated with BVZ in the Netherlands (2009–2021). Progression-free survival, change in visual acuity and visual field, MRI-based radiologic response, and toxicity were evaluated. Results: In total, 33 pediatric patients with OPG were treated with BVZ (median 12 months). Visual acuity improved in 20.5%, remained stable in 74.4%, and decreased in 5.1% of 39 of all analysed eyes. The monocular visual field improved in 73.1%, remained stable in 15.4%, and decreased in 7.7% of 25 analysed eyes. Radiologic response at the end of therapy showed a partial response in 7 patients (21.9%), minor response in 7 (21.9%), stable disease in 15 (46.9%), and progressive disease in 3 (9.3%). Progression-free survival at 18 and 36 months after the start of BVZ reduced from 70.9% to 38.0%. Toxicity (≥grade 3 CTCAE) during treatment was observed in five patients (15.2%). Conclusion: Treatment of BVZ in pediatric patients with OPG revealed stabilisation in the majority of patients, but was followed by progression at a later time point in more than 60% of patients. This profile seems relatively acceptable given the benefits of visual field improvement in more than 70% of analysed eyes and visual acuity improvement in more than 20% of eyes at the cessation of BVZ. |
| first_indexed | 2024-03-09T17:14:35Z |
| format | Article |
| id | doaj.art-a44b8d4eee9e411fa42d754b99cee93b |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T17:14:35Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-a44b8d4eee9e411fa42d754b99cee93b2023-11-24T13:45:56ZengMDPI AGCancers2072-66942022-12-011424608710.3390/cancers14246087Impact of Bevacizumab on Visual Function, Tumor Size, and Toxicity in Pediatric Progressive Optic Pathway Glioma: A Retrospective Nationwide Multicentre StudyCarlien A. M. Bennebroek0Judith van Zwol1Giorgio L. Porro2Rianne Oostenbrink3Anne T. M. Dittrich4Annabel L. W. Groot5Jan W. Pott6Etienne J. M. Janssen7Noël J. Bauer8Maria M. van Genderen9Peerooz Saeed10Maarten H. Lequin11Pim de Graaf12Antoinette Y. N. Schouten-van Meeteren13Department of Ophthalmology, Amsterdam UMC Location University of Amsterdam, 1053 VE Amsterdam, The NetherlandsDepartment of Ophthalmology, Amsterdam UMC Location University of Amsterdam, 1053 VE Amsterdam, The NetherlandsDepartment of Ophthalmology Utrecht UMC, 3584 CX Utrecht, The NetherlandsENCORE-NF1 Center, Department of General Pediatrics, Erasmus MC, 3015 GD Rotterdam, The NetherlandsDepartment of Pediatrics, Radboud University Medical Center, Amalia Children’s Hospital, 6525 GA Nijmegen, The NetherlandsDepartment of Ophthalmology, Radboud University Medical Center, 6525 GA Nijmegen, The NetherlandsDepartment of Ophthalmology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The NetherlandsDepartment of Neurology, Maastricht University Medical Center, 6221 CZ Maastricht, The NetherlandsDepartment of Ophthalmology, Maastricht University Medical Center, 6229 HX Maastricht, The NetherlandsDepartment of Ophthalmology Utrecht UMC, 3584 CX Utrecht, The NetherlandsDepartment of Ophthalmology, Amsterdam UMC Location University of Amsterdam, 1053 VE Amsterdam, The NetherlandsDepartment of Radiology, Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The NetherlandsDepartment of Radiology and Nuclear Medicine, Amsterdam UMC Location Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The NetherlandsDepartment of Neuro-Oncology, Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The NetherlandsBackgrounds: Bevacizumab (BVZ) is used as a subsequent line of treatment for pediatric optic pathway glioma (OPG) in the case of progression. Data on the treatment effect concerning tumor progression and visual function are scarce and nationwide studies are lacking. Methods: We performed a retrospective, nationwide, multicentre cohort study including all pediatric patients with OPG treated with BVZ in the Netherlands (2009–2021). Progression-free survival, change in visual acuity and visual field, MRI-based radiologic response, and toxicity were evaluated. Results: In total, 33 pediatric patients with OPG were treated with BVZ (median 12 months). Visual acuity improved in 20.5%, remained stable in 74.4%, and decreased in 5.1% of 39 of all analysed eyes. The monocular visual field improved in 73.1%, remained stable in 15.4%, and decreased in 7.7% of 25 analysed eyes. Radiologic response at the end of therapy showed a partial response in 7 patients (21.9%), minor response in 7 (21.9%), stable disease in 15 (46.9%), and progressive disease in 3 (9.3%). Progression-free survival at 18 and 36 months after the start of BVZ reduced from 70.9% to 38.0%. Toxicity (≥grade 3 CTCAE) during treatment was observed in five patients (15.2%). Conclusion: Treatment of BVZ in pediatric patients with OPG revealed stabilisation in the majority of patients, but was followed by progression at a later time point in more than 60% of patients. This profile seems relatively acceptable given the benefits of visual field improvement in more than 70% of analysed eyes and visual acuity improvement in more than 20% of eyes at the cessation of BVZ.https://www.mdpi.com/2072-6694/14/24/6087bevacizumaboptic pathway gliomalow grade gliomachildsystemic anticancer therapyvisual function |
| spellingShingle | Carlien A. M. Bennebroek Judith van Zwol Giorgio L. Porro Rianne Oostenbrink Anne T. M. Dittrich Annabel L. W. Groot Jan W. Pott Etienne J. M. Janssen Noël J. Bauer Maria M. van Genderen Peerooz Saeed Maarten H. Lequin Pim de Graaf Antoinette Y. N. Schouten-van Meeteren Impact of Bevacizumab on Visual Function, Tumor Size, and Toxicity in Pediatric Progressive Optic Pathway Glioma: A Retrospective Nationwide Multicentre Study Cancers bevacizumab optic pathway glioma low grade glioma child systemic anticancer therapy visual function |
| title | Impact of Bevacizumab on Visual Function, Tumor Size, and Toxicity in Pediatric Progressive Optic Pathway Glioma: A Retrospective Nationwide Multicentre Study |
| title_full | Impact of Bevacizumab on Visual Function, Tumor Size, and Toxicity in Pediatric Progressive Optic Pathway Glioma: A Retrospective Nationwide Multicentre Study |
| title_fullStr | Impact of Bevacizumab on Visual Function, Tumor Size, and Toxicity in Pediatric Progressive Optic Pathway Glioma: A Retrospective Nationwide Multicentre Study |
| title_full_unstemmed | Impact of Bevacizumab on Visual Function, Tumor Size, and Toxicity in Pediatric Progressive Optic Pathway Glioma: A Retrospective Nationwide Multicentre Study |
| title_short | Impact of Bevacizumab on Visual Function, Tumor Size, and Toxicity in Pediatric Progressive Optic Pathway Glioma: A Retrospective Nationwide Multicentre Study |
| title_sort | impact of bevacizumab on visual function tumor size and toxicity in pediatric progressive optic pathway glioma a retrospective nationwide multicentre study |
| topic | bevacizumab optic pathway glioma low grade glioma child systemic anticancer therapy visual function |
| url | https://www.mdpi.com/2072-6694/14/24/6087 |
| work_keys_str_mv | AT carlienambennebroek impactofbevacizumabonvisualfunctiontumorsizeandtoxicityinpediatricprogressiveopticpathwaygliomaaretrospectivenationwidemulticentrestudy AT judithvanzwol impactofbevacizumabonvisualfunctiontumorsizeandtoxicityinpediatricprogressiveopticpathwaygliomaaretrospectivenationwidemulticentrestudy AT giorgiolporro impactofbevacizumabonvisualfunctiontumorsizeandtoxicityinpediatricprogressiveopticpathwaygliomaaretrospectivenationwidemulticentrestudy AT rianneoostenbrink impactofbevacizumabonvisualfunctiontumorsizeandtoxicityinpediatricprogressiveopticpathwaygliomaaretrospectivenationwidemulticentrestudy AT annetmdittrich impactofbevacizumabonvisualfunctiontumorsizeandtoxicityinpediatricprogressiveopticpathwaygliomaaretrospectivenationwidemulticentrestudy AT annabellwgroot impactofbevacizumabonvisualfunctiontumorsizeandtoxicityinpediatricprogressiveopticpathwaygliomaaretrospectivenationwidemulticentrestudy AT janwpott impactofbevacizumabonvisualfunctiontumorsizeandtoxicityinpediatricprogressiveopticpathwaygliomaaretrospectivenationwidemulticentrestudy AT etiennejmjanssen impactofbevacizumabonvisualfunctiontumorsizeandtoxicityinpediatricprogressiveopticpathwaygliomaaretrospectivenationwidemulticentrestudy AT noeljbauer impactofbevacizumabonvisualfunctiontumorsizeandtoxicityinpediatricprogressiveopticpathwaygliomaaretrospectivenationwidemulticentrestudy AT mariamvangenderen impactofbevacizumabonvisualfunctiontumorsizeandtoxicityinpediatricprogressiveopticpathwaygliomaaretrospectivenationwidemulticentrestudy AT peeroozsaeed impactofbevacizumabonvisualfunctiontumorsizeandtoxicityinpediatricprogressiveopticpathwaygliomaaretrospectivenationwidemulticentrestudy AT maartenhlequin impactofbevacizumabonvisualfunctiontumorsizeandtoxicityinpediatricprogressiveopticpathwaygliomaaretrospectivenationwidemulticentrestudy AT pimdegraaf impactofbevacizumabonvisualfunctiontumorsizeandtoxicityinpediatricprogressiveopticpathwaygliomaaretrospectivenationwidemulticentrestudy AT antoinetteynschoutenvanmeeteren impactofbevacizumabonvisualfunctiontumorsizeandtoxicityinpediatricprogressiveopticpathwaygliomaaretrospectivenationwidemulticentrestudy |